Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto ...
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling ...
Advances in Bladder Cancer: innovation in diagnostics, therapeutic technology, and clinical pathways
Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...
Understand the signs of premature ovarian failure and POI. Learn how to manage symptoms and protect your long-term health.
Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...
The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.
The post HYD Pioneers New Research Revealing Systemic Role of Deuterium-Depleted Water in Cancer Therapy appeared first on ...
GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMDCTx001 is an investigational ...
Androgenetic alopecia (AGA) is the most common form of hair loss, affecting 23–87% of the global population. It is driven by genetic predisposition ...
Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion ...
Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...
CanVeer Biopharma Inc. (the “Company” or “CanVeer”), a biopharma company advancing innovative therapeutics for severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results